Vanessa acquires Hungaro-Gal re Shylicine®

Vanessa Research (VRI) has acquired Hungaro-Gal, a Hungarian pharmaceutical contract manufacturing company.

Per the acquisition, VRI will continue Hungaro-Gal’s contract manufacturing services and intends to maintain and grow their existing customer base. Additionally, VRI plans to utilize their facilities to produce Shylicine®, the company’s investigational oral solution developed to treat the rare and lethal microvillus inclusion disease. more